This investigational drug is moving ahead in Phase III trials for late-stage chemotherapy resistant ovarian cancer. A company press release says findings from a study to be presented at the New Zealand Society of Oncology meeting May 9-11, “help explain the mechanism by which phenoxodiol induces cancer cell death.” More at Marshall Edwards Announces … Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death May 1, 2007.